Ricerca

HOMEPAGE

1. Licari A et al. Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents. Paediatr Drugs. 2020 Jun;22(3):295-310.

DUPIXENT NELL’ASMA GRAVE

Che cos’è Dupixent

1. Busse WW et al. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. Adv Ther. 2018 May;35(5):737-748.
2. Corren J et al. Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Ann Allergy Asthma Immunol. 2019 Jan;122(1):41-49.e2.
3. Global Initiative for Asthma. Diagnosis and Management of Difficult-to-treat and Severe Asthma in adolescent and adult patients. v2.0 April 2019, Pocket Guide.
4. Canonica GW. Type 2 Inflammation and the Evolving Profile of Uncontrolled Persistent Asthma. EMJ. 2018;3[4]:24-33.
5. Dupixent®. Riassunto delle Caratteristiche del Prodotto.

Meccanismo d’azione

1. Pelaia C et al. Dupilumab for the treatment of asthma. Expert Opin Biol Ther. 2017 Dec;17(12):1565-1572.
2. Corren J et al. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. J Allergy Clin Immunol Pract. 2020 Feb;8(2):516-526.
3. Robinson D et al. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017 Feb;47(2):161-175.
4. Vatrella A et al. Dupilumab: a novel treatment for asthma. J Asthma Allergy. 2014 Sep 4;7:123-30.
5. Dupixent®. Riassunto delle Caratteristiche del Prodotto.
6. Gandhi NA et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 2016;15(1):35-50.

Efficacia, Sicurezza e Posologia

1. Corren J et al. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. J Allergy Clin Immunol Pract. 2020 Feb;8(2):516-526.
2. Bourdin A et al. Allergy. 2020 Oct 3. doi: 10.1111/all.14611. Epub ahead of print.
3. Bourdin A et al. Allergy. 2020 Oct 3. doi: 10.1111/all.14611. Epub ahead of print. Supplementary.
4. Rabe KF et al. N Engl J Med. 2018;378(26):2475-2485.
5. Rabe KF et al. N Engl J Med. 2018;378(26):2475-2485. Supplementary.
6. Dupixent®. Riassunto delle Caratteristiche del Prodotto.
7. Corren J et al. Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Ann Allergy Asthma Immunol. 2019 Jan;122(1):41-49.e2.
8. Doran E et al. Interleukin-13 in Asthma and Other Eosinophilic Disorders. Front Med (Lausanne). 2017 Sep 19;4:139.

Piano Terapeutico e RCP

1. Piano terapeutico AIFA per la prescrizione SSN di Dupixent® nell’asma grave con infiammazione di Tipo 2.
2. Dupixent®. Riassunto delle Caratteristiche del Prodotto.

DUPIXENT NELLA POLIPOSI NASALE GRAVE

Che cos’è Dupixent

1. Busse WW et al. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. Adv Ther. 2018 May;35(5):737-748.
2. EMA - Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019. https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2019. (Ultimo accesso: 23/11/2020).
3. Dupixent®. Riassunto delle Caratteristiche del Prodotto.
4. Bachert C et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019 Nov 2; 394(10209):1638-1650.

Meccanismo d’azione

1. Corren J et al. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. J Allergy Clin Immunol Pract. 2020 Feb;8(2):516-526.
2. Chaaban MR et al. Epidemiology and differential diagnosis of nasal polyps. Am J Rhinol Allergy. Nov-Dec 2013;27(6):473-8.
3. Gandhi NA et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 2016;15(1):35-50.
4. Schleimer RP. Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis. Annu Rev Pathol. 2017;12:331-357.
5. Vatrella A et al. Dupilumab: a novel treatment for asthma. J Asthma Allergy. 2014 Sep 4;7:123-30.
6. Dupixent®. Riassunto delle Caratteristiche del Prodotto.

Efficacia, Sicurezza e Posologia

1. Dupixent®. Riassunto delle Caratteristiche del Prodotto.
2. Bachert C et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019 Nov 2; 394(10209):1638-1650.
3. Bachert C, et al. Lancet 2019 Nov 2; 394(10209):1638-1650. Supplementary.
4. Kang XR et al. A prediction modeling based on SNOT-22 score for endoscopic nasal septoplasty: a retrospective study. PeerJ 2020 Sep 11;8:e9890.
5. Dupixent®. Foglio illustrativo.

Piano Terapeutico e RCP

1. Piano terapeutico AIFA per la prescrizione SSN di Dupixent® (dupilumab) nella CRSwNP.